Status: Recruiting
A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis
This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation of the clinical effectiveness of BD111 in combination with standard therapy.
Participants needed: 40
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Shanghai BDgene Co., Ltd.Updated: May 18, 2025Locations: 1
Eligibility criteria
Aged 18 to 70 years old; [+11]
Active ocular infection caused by other pathogens in the target eye or the fello... [+21]